Atika Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Atika Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.32M	Buy	+12,900	New	+$4.08M	0.28%	65

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Atika Capital Management's PRAX Position: Q2 2026 in Review

Atika Capital Management opened a new position in Praxis Precision Medicines (PRAX) in Q2 2026: 12,900 shares worth $4.32M. The stake represents 0.28% of the portfolio and ranks #65 among its holdings.

309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Atika Capital Management held 12,900 shares of Praxis Precision Medicines worth $4.32M as of Q2 2026.
Praxis Precision Medicines was a new Atika Capital Management position in Q2 2026.
Praxis Precision Medicines made up 0.28% of Atika Capital Management's portfolio in Q2 2026, its #65 holding.
309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Atika Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.